Concepedia

Author

Amarjot Kaur

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

AMARJOT KAUR, Amarjot Kaur, Kaur, Amarjot

104

Publications

3.9K

Citations

32

H-Index

58

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Bernstein Clinical Research CenterUniversity of CincinnatiNational Jewish HealthUniversity of Colorado Denver
AK

About

Amarjot Kaur is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, immunotherapy, and allergy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

18

1.7K

2

Allergy

7

7

677

3

Public Health

2

2

177

4

Health Sciences

1

1

24

5

Social Sciences

1

1

27

Amarjot Kaur

×

28

Publications

2.3K

Citations

23

H-Index

YearCitations

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

Christopher P. Cannon, Sean Curtis, Garret A. FitzGerald,

The Lancet

2006

520

Alendronate and Estrogen–Progestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial

Pernille Ravn, Marianne Bidstrup, Richard D. Wasnich,

Annals of Internal Medicine

1999

186

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults

Peter S. Creticos, Jennifer Maloney, David I. Bernstein,

Journal of Allergy and Clinical Immunology

2013

167

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber

Hendrik Nolte, Jennifer Maloney, Harold S. Nelson,

Journal of Allergy and Clinical Immunology

2015

158

Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial

Jennifer Maloney, David I. Bernstein, Harold S. Nelson,

Annals of Allergy Asthma & Immunology

2013

156

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial

Hendrik Nolte, David I. Bernstein, Harold S. Nelson,

Journal of Allergy and Clinical Immunology

2016

142

Lower Gastrointestinal Events in a Double-Blind Trial of the Cyclo-Oxygenase-2 Selective Inhibitor Etoricoxib and the Traditional Nonsteroidal Anti-Inflammatory Drug Diclofenac

Loren Laine, Sean Curtis, M. J. S. Langman,

Gastroenterology

2008

133

Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults

Hendrik Nolte, Jacques Hébert, Gary Berman,

Annals of Allergy Asthma & Immunology

2013

97

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

Herbert S. B. Baraf, Carlos Fuentealba, Maria Greenwald,

PubMed

2007

80

Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated

Jennifer Maloney, Gary Berman, Rémi Gagnon,

The Journal of Allergy and Clinical Immunology In Practice

2016

55

Page 1